Next Article in Journal
Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials
Next Article in Special Issue
Oleic Acid-Containing Phosphatidylinositol Is a Blood Biomarker Candidate for SPG28
Previous Article in Journal
Gq-Mediated Arrhythmogenic Signaling Promotes Atrial Fibrillation
Previous Article in Special Issue
Molecular Abnormalities in BTBR Mice and Their Relevance to Schizophrenia and Autism Spectrum Disorders: An Overview of Transcriptomic and Proteomic Studies
 
 
Article
Peer-Review Record

Towards Standardisation of a Diffuse Midline Glioma Patient-Derived Xenograft Mouse Model Based on Suspension Matrices for Preclinical Research

Biomedicines 2023, 11(2), 527; https://doi.org/10.3390/biomedicines11020527
by Elvin ’t Hart 1, John Bianco 1, Helena C. Besse 2, Lois A. Chin Joe Kie 1, Lesley Cornet 1, Kimberly L. Eikelenboom 1, Thijs J.M. van den Broek 1, Marc Derieppe 1, Yan Su 1, Eelco W. Hoving 1, Mario G. Ries 2,† and Dannis G. van Vuurden 1,*,†
Reviewer 1:
Reviewer 2: Anonymous
Reviewer 3:
Biomedicines 2023, 11(2), 527; https://doi.org/10.3390/biomedicines11020527
Submission received: 15 December 2022 / Revised: 31 January 2023 / Accepted: 9 February 2023 / Published: 11 February 2023
(This article belongs to the Special Issue Animal Models of Human Pathology: Revision, Relevance and Refinements)

Round 1

Reviewer 1 Report

Towards standardisation of a diffuse midline glioma patient- 2 derived xenograft mouse model based on suspension matrices 3 for preclinical research IS EXCELLENT Manuscript. Will be useful for Glioblastoma Research

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

The manuscript is related to preclinical model development for midline glioma and used materials for inoculation of cells to the mice. They have been used the suspansion of cells to intracranium by using matrigel or PBS. Then they  have evaluted the tumor growth, survival and metastases. They have only showed the delayed metastases by using matrigel treatment compared to PBS treated group. The issue of manuscript is very simple for development of patient derived xenograft models for gliomas. Also, the manuscript does not give us any new data for the application of PDX models for gliomas. So that, it can not acceptable for the publication.

 

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 3 Report

The paper is really reliably prepared, a this is hard to show weak points. The only thing which is lacking for me is a scale bar showing the relationship between BLI intensity and colour in Figure 2.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Back to TopTop